IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER
Kidney Diseases
Celldex Therapeuticsmonoclonal_antibodyPhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 23/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Kidney Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
su011248 AstraZeneca | Phase 3 | B |
nc-503 Bellus Health Inc. - a GSK company | Phase 2/3 | B |
VOLITINIB AstraZeneca | Phase 3 | B |
SEVELAMER Genzyme, a Sanofi Company | Phase 3 | B |
NKT2152 NiKang Therapeutics, Inc. | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →